Allelica

Valor Backs Genomics SaaS Platform Allelica 

Allelica brings precision medicine into mainstream clinical practice through a Software-as-a-Service platform for the prediction of complex, genetic diseases using proprietary polygenic risk scores. With major customers across three continents, Allelica is poised to be the first mass adoption of precision medicine.

Allelica’s co-founders include two of the world’s leading genomic bioinformaticians and Polygenic Risk Score (PRS) scientists, CEO Giordano Bottà, Ph.D. and Chief Science Officer, George Busby, Ph.D., plus data scientist Paolo Di Domenico, Ph.D.  Their fundamental research contributions helped develop the algorithms and AI that make genomic analysis possible at scale.With this round, Allelica has hired a Baltimore-based sales leader, Edgar Carter, as VP of Sales.  Valor General Partner Gary Peat joins the Allelica board of directors. 

Allelica uses genomic data to stratify individuals with different trajectories of future disease risk based upon your entire genome.

This offers the potential to complement and improve conventional risk prediction and clinical practices in specialties and subspecialties such as fertility, cardiology, oncology, pediatrics, neurology, and more.  Allelica’s platform democratizes access to personalized medicine through AI and analytics at scale which promises to save lives, prolong healthy lives, and reduce the incidence of chronic disease during your lifetime .

Allelica is a research-forward software company focused on genomics.

It builds efficient and scalable solutions for clinically accessible polygenic risk scores (PRSs). Allelica technology combines world-class datasets with its own patented risk algorithms. Through the incorporation of genetics into disease risk assessments, Allelica is helping to build the foundations of preventative medicine by identifying those who benefit the most from early intervention and behavior modification to reduce lifetime risk. In an era where gender and racial prejudices in medicine contribute to poorer outcomes, personalized medicine based on DNA can help remove bias in medicine and help more people heal with clear data about their unique, personalized healthcare needs. Allelica makes genetics-driven risk predictions available to healthcare professionals through a SaaS platform available worldwide.

Says Gary Peat, Valor general partner, “Allelica brings precision medicine into mainstream clinical practice through a Software-as-a-Service platform for the prediction of complex, genetic diseases using proprietary polygenic risk scores.  With major customers across three continents, Allelica is poised to be the first mass adoption of precision medicine. For example, in cardiology, Allelica has partnered with a leader in therapies for Coronary Artery Disease, Merck, to develop data-driven cardiovascular disease-risk stratification tools based upon Allelica’s polygenic risk scores for Coronary Artery Disease.”

You can see some of the clinical outcomes from Allelica’s platform in the peer-reviewed scientific journal of the American Heart Association, Circulation.

 

 

Allelica

Valor Backs Genomics SaaS Platform Allelica 

Allelica brings precision medicine into mainstream clinical practice through a Software-as-a-Service platform for the prediction of complex, genetic diseases using proprietary polygenic risk scores. With major customers across three continents, Allelica is poised to be the first mass adoption of precision medicine.

Allelica’s co-founders include two of the world’s leading genomic bioinformaticians and Polygenic Risk Score (PRS) scientists, CEO Giordano Bottà, Ph.D. and Chief Science Officer, George Busby, Ph.D., plus data scientist Paolo Di Domenico, Ph.D.  Their fundamental research contributions helped develop the algorithms and AI that make genomic analysis possible at scale.With this round, Allelica has hired a Baltimore-based sales leader, Edgar Carter, as VP of Sales.  Valor General Partner Gary Peat joins the Allelica board of directors. 

Allelica uses genomic data to stratify individuals with different trajectories of future disease risk based upon your entire genome.

This offers the potential to complement and improve conventional risk prediction and clinical practices in specialties and subspecialties such as fertility, cardiology, oncology, pediatrics, neurology, and more.  Allelica's platform democratizes access to personalized medicine through AI and analytics at scale which promises to save lives, prolong healthy lives, and reduce the incidence of chronic disease during your lifetime .

Allelica is a research-forward software company focused on genomics.

It builds efficient and scalable solutions for clinically accessible polygenic risk scores (PRSs). Allelica technology combines world-class datasets with its own patented risk algorithms. Through the incorporation of genetics into disease risk assessments, Allelica is helping to build the foundations of preventative medicine by identifying those who benefit the most from early intervention and behavior modification to reduce lifetime risk. In an era where gender and racial prejudices in medicine contribute to poorer outcomes, personalized medicine based on DNA can help remove bias in medicine and help more people heal with clear data about their unique, personalized healthcare needs. Allelica makes genetics-driven risk predictions available to healthcare professionals through a SaaS platform available worldwide.

Says Gary Peat, Valor general partner, “Allelica brings precision medicine into mainstream clinical practice through a Software-as-a-Service platform for the prediction of complex, genetic diseases using proprietary polygenic risk scores.  With major customers across three continents, Allelica is poised to be the first mass adoption of precision medicine. For example, in cardiology, Allelica has partnered with a leader in therapies for Coronary Artery Disease, Merck, to develop data-driven cardiovascular disease-risk stratification tools based upon Allelica’s polygenic risk scores for Coronary Artery Disease.”

You can see some of the clinical outcomes from Allelica's platform in the peer-reviewed scientific journal of the American Heart Association, Circulation.

 

 

Baltimore, MD